NCT05291689CompletedPhase 2
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1)
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- First submitted
- 10 Mar 2022
- Start date
- 13 Apr 2022
- Primary completion date
- 18 Oct 2023
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Diseases
- Ulcerative colitis
- NCT number
- NCT05291689
- EU CT number
- 2024-516960-27-00
- EudraCT number
- 2021-005288-31
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 39
- From 13 Apr 2022 to the primary completion date, 18 Oct 2023
- 6 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has a concurrent, clinically significant, serious, unstable comorbidity
- Primary non-responder to vedolizumab or other integrin inhibitors
- Participation in any other interventional study or received any investigational therapy within 30 days
- Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with a similar mechanism to MORF-057
Other illness
- Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or Crohn's disease or has clinical findings suggestive of Crohn's disease
Other
- Has positive findings on a subjective neurological screening questionnaire
- Unable to attend study visits or comply with study procedures
Who the study is looking for
- Has signs/symptoms of moderately to severely active UC for at least 3 months prior to Screening
- Has evidence of UC extending at least 15 cm from the anal verge
- Is bio-naïve or had an inadequate response, loss of response, or intolerance to other UC drugs
- Agrees to abide by the study guidelines and requirements
- Capable of giving signed informed consent
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Specjalistyczna Praktyka Lekarska dr med. Marek Horyński Coordinator of this site? Confirm its status | Sopot | Poland | Completed |
| - Coordinator of this site? Confirm its status | Brooklyn | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Freehold | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Lafayette | United States | Unknown status |
| - Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.